Related references
Note: Only part of the references are listed.Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group
Ashutosh D. Wechalekar et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2023)
Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumab
Raphael E. Szalat et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
Tissue biopsy for the diagnosis of amyloidosis: experience from some centres
Merrill D. Benson et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2022)
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines
Vaishali Sanchorawala et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2022)
Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study
Ashutosh Wechalekar et al.
BMC CARDIOVASCULAR DISORDERS (2022)
Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: results from a large cohort of patients
Marco Basset et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2022)
How I treat AL amyloidosis
Giovanni Palladini et al.
BLOOD (2022)
Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis
Oliver C. Cohen et al.
EUROPEAN HEART JOURNAL (2022)
A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis
Angela Dispenzieri et al.
LEUKEMIA (2022)
Belantamab mafodotin in patients with relapsed/refractory AL amyloidosis with myeloma
Yifei Zhang et al.
ANNALS OF HEMATOLOGY (2022)
Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival
Marco Basset et al.
BLOOD (2022)
Prognostic importance of the 6 min walk test in light chain (AL) amyloidosis
Oliver C. Cohen et al.
HEART (2022)
Birtamimab in patients with Mayo stage IV AL amyloidosis: Rationale for confirmatory affirm-AL phase 3 study.
Morie A. Gertz et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis
Mario Nuvolone et al.
BIODRUGS (2022)
Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
Shlomit Kfir-Erenfeld et al.
CLINICAL CANCER RESEARCH (2022)
High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis
Jahanzaib Khwaja et al.
BLOOD CANCER JOURNAL (2022)
Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment
Ana Martinez-Naharro et al.
EUROPEAN HEART JOURNAL (2022)
Heterogenous mutation spectrum and deregulated cellular pathways in aberrant plasma cells underline molecular pathology of light-chain amyloidosis
Zuzana Chyra et al.
HAEMATOLOGICA (2021)
Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis
Isabel Cuenca et al.
LEUKEMIA (2021)
Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis
Efstathios Kastritis et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2021)
Next generation flow cytometry for MRD detection in patients with AL amyloidosis
Esftathios Kastritis et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2021)
Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis
Giovanni Palladini et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2021)
Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival
Eli Muchtar et al.
BLOOD (2021)
Graded Renal Response Criteria for Light Chain (AL) Amyloidosis
Eli Muchtar et al.
BLOOD (2021)
Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network
Efstathios Kastritis et al.
BLOOD (2021)
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
Vikram J. Premkumar et al.
BLOOD CANCER JOURNAL (2021)
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis
Giovanni Palladini et al.
BLOOD CANCER JOURNAL (2021)
Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21
Christoph R. Kimmich et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma
Aina Oliver-Caldes et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis
Camille Vanessa Edwards et al.
BLOOD (2021)
Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up
Marco Basset et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update
Eli Muchtar et al.
MAYO CLINIC PROCEEDINGS (2021)
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis
E. Kastritis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib
Sriram Ravichandran et al.
BLOOD CANCER JOURNAL (2021)
99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis
Candida Cristina Quarta et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING (2021)
Establishment of brain natriuretic peptide - based criteria for evaluating cardiac response to treatment in light chain (AL) amyloidosis
Brian Lilleness et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Genomic profiling in amyloid light-chain amyloidosis reveals mutation profiles associated with overall survival
Xu-Fei Huang et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2020)
Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study
Vaishali Sanchorawala et al.
BLOOD (2020)
Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria
Christoph R. Kimmich et al.
BLOOD (2020)
Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients
Paolo Milani et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2020)
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study
Constantine S. Tam et al.
BLOOD (2020)
Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis
Efstathios Kastritis et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis
Marco Basset et al.
BLOOD ADVANCES (2020)
Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients
Alissa Visram et al.
BLOOD CANCER JOURNAL (2020)
A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808)
Terri L. Parker et al.
BLOOD (2020)
Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis
Andrew Staron et al.
BLOOD ADVANCES (2020)
Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient
Paolo Swuec et al.
NATURE COMMUNICATIONS (2019)
Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis
Lynn Radamaker et al.
NATURE COMMUNICATIONS (2019)
The sensitivity and specificity of the routine kidney biopsy immunofluorescence panel are inferior to diagnosing renal immunoglobulin-derived amyloidosis by mass spectrometry
Maria L. Gonzalez Suarez et al.
KIDNEY INTERNATIONAL (2019)
Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis
Brian Lilleness et al.
BLOOD (2019)
Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine
Richa Manwani et al.
BLOOD (2018)
Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time
M. Hasib Sidiqi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Deferred autologous stem cell transplantation in systemic AL amyloidosis
Richa Manwani et al.
BLOOD CANCER JOURNAL (2018)
Systemic immunoglobulin light chain amyloidosis
Giampaolo Merlini et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma
Tilmann Bochtler et al.
BLOOD ADVANCES (2018)
First report of ibrutinib in IgM-related amyloidosis: few responses, poor tolerability, and short survival
Tomas Pika et al.
BLOOD (2018)
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies
Giovanni Palladini et al.
BLOOD (2018)
Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry
Taxiarchis V. Kourelis et al.
BLOOD (2017)
Mutational landscape reflects the biological continuum of plasma cell dyscrasias
A. Rossi et al.
BLOOD CANCER JOURNAL (2017)
Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells
Esther Imperlini et al.
SCIENTIFIC REPORTS (2017)
Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity
Luca Oberti et al.
SCIENTIFIC REPORTS (2017)
Attitudes about when and how to treat patients with AL amyloidosis: an international survey
Paolo Milani et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2017)
Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition
Eli Muchtar et al.
ANNALS OF MEDICINE (2017)
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays
Giovanni Palladini et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2017)
Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis
Nidhi Tandon et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Tc-99m Radiolabeled Peptide p5+14 is an Effective Probe for SPECT Imaging of Systemic Amyloidosis
Stephen J. Kennel et al.
MOLECULAR IMAGING AND BIOLOGY (2016)
Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation
Yi L. Hwa et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
Julian D. Gillmore et al.
CIRCULATION (2016)
Bortezomib-induced severe pulmonary complications in multiple myeloma: A case report and literature review
Jingbo Li et al.
ONCOLOGY LETTERS (2016)
Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience
Vaishali Sanchorawala et al.
BLOOD (2015)
A practical approach to the diagnosis of systemic amyloidoses
Carlos Fernandez de Larrea et al.
BLOOD (2015)
A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis
Maria T. Cibeira et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens
Tilmann Bochtler et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias
Taxiarchis V. Kourelis et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis
Giovanni Palladini et al.
BLOOD (2014)
Increased Serum Free Light Chains Precede the Presentation of Immunoglobulin Light Chain Amyloidosis
Brendan M. Weiss et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Systemic light chain amyloidosis: an update for treating physicians
Giampaolo Merlini et al.
BLOOD (2013)
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis
Ashutosh D. Wechalekar et al.
BLOOD (2013)
Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis
M. A. Gertz et al.
BONE MARROW TRANSPLANTATION (2013)
Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients
Stefan O. Schoenland et al.
BLOOD (2012)
The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44
Vittorio Perfetti et al.
BLOOD (2012)
Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue
Francesca Brambilla et al.
BLOOD (2012)
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
Giovanni Palladini et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements
Shaji Kumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Strong Transthyretin Immunostaining: Potential Pitfall in Cardiac Amyloid Typing
Anjali A. Satoskar et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2011)
The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 62 patients
A. Foli et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2011)
Treatment of IgM-Associated AL Amyloidosis With the Combination of Rituximab, Bortezomib, and Dexamethasone
Giovanni Palladini et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2011)
Kidney dysfunction during lenalidomide treatment for AL amyloidosis
Richard Specter et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2011)
Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs
Angela Dispenzieri et al.
AMERICAN JOURNAL OF HEMATOLOGY (2010)
Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens
Julie A. Vrana et al.
BLOOD (2009)
Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine
Giovanni Palladini et al.
CLINICAL CHEMISTRY (2009)
Screening Panels for Detection of Monoclonal Gammopathies
Jerry A. Katzmann et al.
CLINICAL CHEMISTRY (2009)
Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis
Tilmann Bochtler et al.
HAEMATOLOGICA (2008)
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis
Arnaud Jaccard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL
Giovanni Palladini et al.
BLOOD (2006)
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis
A Dispenzieri et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
The tropism of organ involvement in primary systemic amyloidosis:: contributions of Ig VL germ line gene use and clonal plasma cell burden
RL Comenzo et al.
BLOOD (2001)
Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis
SD Yan et al.
NATURE MEDICINE (2000)
Share Paper
